A Phase 3 randomized trial of voxelotor in sickle cell disease

Elliott Vichinsky*, Carolyn C. Hoppe, Kenneth I. Ataga, Russell E. Ware, Videlis Nduba, Amal El-Beshlawy, Hoda Hassab, Maureen M. Achebe, Salam Alkindi, R. Clark Brown, David L. Diuguid, Paul Telfer, Dimitris A. Tsitsikas, Ashraf Elghandour, Victor R. Gordeuk, Julie Kanter, Miguel R. Abboud, Joshua Lehrer-Graiwer, Margaret Tonda, Allison IntondiBarbara Tong, Jo Howard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

92 Citations (Scopus)

Abstract

BACKGROUND Deoxygenated sickle hemoglobin (HbS) polymerization drives the pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has potential to favorably modify disease outcomes. Voxelotor is an HbS polymerization inhibitor. METHODS In a multicenter, phase 3, double-blind, randomized, placebo-controlled trial, we compared the efficacy and safety of two dose levels of voxelotor (1500 mg and 900 mg, administered orally once daily) with placebo in persons with sickle cell disease. The primary end point was the percentage of participants who had a hemoglobin response, which was defined as an increase of more than 1.0 g per deciliter from baseline at week 24 in the intention-to-treat analysis. RESULTS A total of 274 participants were randomly assigned in a 1:1:1 ratio to receive a once-daily oral dose of 1500 mg of voxelotor, 900 mg of voxelotor, or placebo. Most participants had sickle cell anemia (homozygous hemoglobin S or hemoglobin Sß0-thalassemia), and approximately two thirds were receiving hydroxyurea at baseline. In the intention-to-treat analysis, a significantly higher percentage of participants had a hemoglobin response in the 1500-mg voxelotor group (51%; 95% confidence interval [CI], 41 to 61) than in the placebo group (7%; 95% CI, 1 to 12). Anemia worsened between baseline and week 24 in fewer participants in each voxelotor dose group than in those receiving placebo. At week 24, the 1500-mg voxelotor group had significantly greater reductions from baseline in the indirect bilirubin level and percentage of reticulocytes than the placebo group. The percentage of participants with an adverse event that occurred or worsened during the treatment period was similar across the trial groups. Adverse events of at least grade 3 occurred in 26% of the participants in the 1500-mg voxelotor group, 23% in the 900-mg voxelotor group, and 26% in the placebo group. Most adverse events were not related to the trial drug or placebo, as determined by the investigators. CONCLUSIONS In this phase 3 randomized, placebo-controlled trial involving participants with sickle cell disease, voxelotor significantly increased hemoglobin levels and reduced markers of hemolysis. These findings are consistent with inhibition of HbS polymerization and indicate a disease- modifying potential.

Original languageEnglish
Pages (from-to)509-519
Number of pages11
JournalNew England Journal of Medicine
Volume381
Issue number6
DOIs
Publication statusPublished - Aug 8 2019

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A Phase 3 randomized trial of voxelotor in sickle cell disease'. Together they form a unique fingerprint.

Cite this